Project: Novel therapeutic mimotope-AAVLP cancer vaccine engineered using NGS-guided molecular evolution

Acronym MimoVac-E (Reference Number: 12406)
Duration 30/09/2018
Project Topic We will develop a vaccine that mobilizes the patient’s immune system for a potent and long-lasting response against cancer cells in head and neck cancer (HNC), where there is a major unmet medical need. Based on a clinically approved monoclonal antibody, we will develop novel cancer mimotopes displayed numerously on adeno-associated virus-like particles (AAVLP). The vaccine is validated in vitro and preclinically during the project, and successively continued into a clinical phase I study.
Network Eurostars 2
Call Eurostars Cut–off 9

Project partner

Number Name Role Country
1 2A Pharma AB Coordinator Sweden
2 DNASense ApS Partner Denmark
3 Danish Technological Institute Partner Denmark